Trial Profile
An International Phase 1/2 Study of GRT-C901/GRT-R902, a Neoantigen Cancer Vaccine, in Combination With Immune Checkpoint Blockade for Patients With Advanced Solid Tumors
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Apr 2023
Price :
$35
*
At a glance
- Drugs GRANITE 001 (Primary) ; Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Bladder cancer; Colorectal cancer; Gastric cancer; Non-small cell lung cancer; Oesophageal cancer; Solid tumours; Urogenital cancer
- Focus Adverse reactions; First in man; Therapeutic Use
- Sponsors Gritstone bio
- 17 Apr 2023 According to a Gritstone bio media release, company is presenting oral presentations (minisymposium) on highlighted data from GRANITE programs phase 1/2 and phase2/3 trials at the 2023 American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida on April 16.
- 15 Mar 2023 According to a Gritstone bio media release, data from this study will be presented at the 2023 American Association for Cancer Research (AACR) Annual Meeting.
- 15 Feb 2023 Status changed from active, no longer recruiting to completed.